Skip to main content

Table 1 Baseline characteristics of diabetic patients taking metformin plus DPP4i versus other hypoglycemic agents, before and after propensity score weighting

From: Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

  Before weighting After weighting
DPP4i users Non-DPP4i users Standardized mean difference DPP4i users Non-DPP4i users Standardized mean difference
(n = 16,017) (n = 74,863) (n = 16,017) (n = 74,863)
Follow-up time (years)
 Mean ± SD 2.04 ± 1.21 2.41 ± 1.27   2.07 ± 2.90 2.41 ± 1.39  
Age at index date
 Mean ± SD 54.51 ± 12.53 54.88 ± 12.20   54.43 ± 30.16 54.88 ± 13.41  
 < 65 year 80.23% 79.59% 0.0162 79.87% 79.70% 0.0043
 ≥ 65 years 19.77% 20.41%   20.13% 20.30%  
Gender 0.0162    − 0.0008
 Female 42.64% 41.84%   41.95% 41.99%  
History of comorbidity
 Hypertension 58.33% 57.34% 0.0199 57.38% 57.52% − 0.0029
 Hyperlipidemia 59.76% 56.96% 0.0567 57.51% 57.44% 0.0014
 Ischemic heart disease 2.57% 2.02% 0.0386 2.10% 2.11% − 0.0006
 Heart valve surgery 0.09% 0.05% 0.0200 0.05% 0.05% − 0.0032
 Obstructive sleep apnea 0.00% 0.00%   0.00% 0.00%  
 Hyperthyroidism 2.68% 2.08% 0.0406 2.19% 2.19% 0.0003
 Chronic kidney disease 7.56% 7.09% 0.0182 7.11% 7.17% − 0.0024
 PAOD 0.51% 0.36% 0.0239 0.36% 0.39% − 0.0038
 Gout 19.31% 20.61% − 0.0323 20.37% 20.39% − 0.0006
 Chronic lung disease 1.29% 1.35% − 0.0049 1.31% 1.34% − 0.0026
 Congestive heart failure 0.28% 0.13% 0.0355 0.15% 0.16% − 0.0015
Medication
 Beta-blocker 13.78% 13.75% 0.0008 13.67% 13.75% − 0.0026
 Diltiazem/verapamil 3.02% 2.38% 0.0408 2.48% 2.49% − 0.0002
 Statin 33.60% 25.83% 0.1745 27.18% 27.20% − 0.0005
 ACEI/ARB 36.62% 30.55% 0.1305 31.66% 31.61% 0.0012
  1. ACEI angiotensin-converting-enzyme inhibitor, AF atrial fibrillation, ARB angiotensin II receptor antagonists, CI confidence interval, DM diabetes mellitus, DPP4i dipeptidyl peptidase-4 inhibitor, GLP-1 glucagon-like peptide-1, PAOD peripheral arterial obstructive disease, TZD thiazolidinedione